All Updates

All Updates

icon
Filter
Funding
Paradigm raises USD 203 million in Series A funding
Clinical Trial Technology
Jan 31, 2023
This week:
Partnerships
Apple discloses use of AWS GenAI chips at re:Invent 2024 conference
Generative AI Infrastructure
Today
Product updates
AWS launches Automated Reasoning checks to combat AI hallucinations
Generative AI Infrastructure
Today
Product updates
Roonyx releases enhanced BNPL platform to facilitate secure transactions
Buy Now, Pay Later
Yesterday
Product updates
AWS announces next generation of SageMaker platform at re:Invent 2024
Generative AI Infrastructure
Yesterday
Product updates
Equal1 launches quantum controller chip for cryogenic computing
Quantum Computing
Yesterday
Partnerships
Exotec partners with BlueStar to deploy Skypod warehouse automation system
Logistics Tech
Yesterday
Partnerships
Amaero enters long-term supply agreement with Perryman
Additive Manufacturing
Yesterday
Product updates
Raise3D launches six new resins for DF2 DLP solution
Additive Manufacturing
Yesterday
M&A
Anzu Partners acquires voxeljet for EUR 20 million
Additive Manufacturing
Yesterday
Funding
Soda Health raises USD 50 million in oversubscribed Series B funding to scale operations
Health Benefits Platforms
Yesterday
Clinical Trial Technology

Clinical Trial Technology

Jan 31, 2023

Paradigm raises USD 203 million in Series A funding

Funding

  • Patient recruitment company, Paradigm, has launched out of stealth, raising USD 203 million in Series A funding. The raise was co-led by Arch Venture Partners and General Catalyst, with participation from other venture capital funds.

  • The funds raised are to be used to develop its platform and accelerate partnerships with health systems and life sciences companies. Additionally, Paradigm has announced the acquisition of oncology patient recruitment platform, Deep Lens.

  • Paradigm is a clinical trial technology company seeking to improve the patient recruitment process by integrating healthcare electronic health records with clinical trial recruitment systems. The company seeks to improve the data collection process through automation and AI, making it easier for physicians to maintain records. In terms of monetization, the company will not charge healthcare companies for using the platform; instead, it aims to charge pharmaceutical companies that use the platform to find patients for clinical trials.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.